Perceptive Advisors

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

OnKure Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative cancer therapies. The company specializes in creating less toxic kinase inhibitor drugs and epigenetic therapies, including selective inhibitors of histone deacetylases. Its lead candidate, OKI-179, has demonstrated significant efficacy in preclinical models of hematological and solid tumor cancers, effectively reducing tumor growth both alone and in combination with other targeted therapies. Additionally, OnKure is advancing its HDAC3 selective inhibitor, OKI-422, into preclinical toxicology studies. The company's drug candidates are designed to directly target malignant cells, enhance the effects of small molecule therapies, and optimize the tumor microenvironment for improved checkpoint inhibition, addressing unmet medical needs in cancer treatment.

Orpyx Medical Technologies Inc. specializes in developing mobility sensor devices aimed at diabetic patients. The company's flagship product, the Orpyx SI sensory insoles, employs advanced sensor technology to monitor pressure, temperature, and movement, thereby helping to manage and prevent diabetic foot ulcers and limb loss. Additionally, Orpyx offers Kinetyx, a mobile in-shoe pressure management system that captures clinical plantar pressure data for sports medicine and footwear design, along with SurroGait Rx, which aids multiple sclerosis patients in enhancing mobility and balance. Founded in 2010 and headquartered in Calgary, Canada, Orpyx Medical Technologies is committed to empowering individuals with diabetes to maintain their mobility while promoting a prevention-focused healthcare model.

InSightec Ltd. specializes in developing and distributing the Exablate platform, which employs MR-guided focused ultrasound technology for non-invasive medical treatments in oncology and gynecology. The company offers solutions such as Exablate Neuro, designed for personalized thalamotomy to address movement disorders and pain without invasive surgery, and a thermal ablation technique for the treatment of uterine fibroids, which alleviates symptoms while minimizing damage to surrounding tissues. Founded in 1999 and headquartered in Tirat Carmel, Israel, InSightec has expanded its presence globally with operations in Europe, Asia, and the Americas. The Exablate system has received various regulatory approvals, including CE marks and FDA approval, and has been recognized with multiple innovation awards for its contributions to healthcare. In addition to its medical devices, InSightec provides clinical training, business support, maintenance, and customer services to healthcare facilities using its technology.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

CereVasc, Inc. is a medical device company dedicated to developing innovative, minimally invasive treatments for neurological diseases. Founded in 2014 and based in Auburndale, Massachusetts, the company focuses on its flagship product, the eShunt System. This system provides an endovascularly deliverable cerebrospinal fluid shunt along with necessary delivery components, designed to eliminate the need for invasive surgical procedures, general anesthesia, and prolonged hospitalization associated with traditional treatments for communicating hydrocephalus. By offering a less invasive option, the eShunt System aims to enhance patient outcomes and reduce the overall costs of surgical interventions for this serious condition.

Adaptilens, LLC is focused on developing an injectable, physiologically adaptive intraocular lens that provides patients with clear vision at various distances without the need for eyeglasses or contact lenses. Incorporated in 2019 and based in Chestnut Hill, Massachusetts, the company's innovative lens mimics the function of the natural human lens, allowing the ciliary muscles within the eye to alter the shape of the lens. This unique design enables natural accommodation, enabling users to focus on both near and distant objects effectively. Adaptilens aims to enhance the quality of life for patients by offering a solution that facilitates excellent near, intermediate, and distance vision.

Mainstay Medical, based in Dublin, Ireland, with operations in the U.S. and Australia, is a medical device company specializing in the development and commercialization of innovative treatments for chronic low back pain. Its flagship product, ReActiv8, is an implantable neurostimulation system designed to restore muscle control and improve function in the lumbar spine, thereby enhancing patients' quality of life. Founded in 2008, the company collaborates with scientists and clinical experts to address the significant unmet need in this large, underserved patient population.

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

Apyx Medical Corp is a medical device company focused on energy technology, dedicated to developing, manufacturing, and marketing a variety of surgical and cosmetic products. The company is known for its innovative Renuvion cosmetic technology, which enables plastic and cosmetic surgeons to apply controlled heat to tissues, achieving desired aesthetic results with minimal invasiveness. Apyx Medical's flagship J-Plasma system utilizes a patented helium ionization process to generate a stable, focused beam of plasma, allowing for precise cutting, coagulation, and ablation of soft tissue while minimizing unintended damage to surrounding areas. Apyx Medical’s products are utilized in a range of settings, including doctor's offices, surgery centers, and hospitals, highlighting the company's commitment to enhancing surgical outcomes through advanced medical technologies.

enVVeno Medical Corp is a medical device company dedicated to advancing the treatment of venous disease through the development of bioprosthetic devices. The company's flagship product, the VenoValve, represents a pioneering surgical implant designed to address severe deep venous Chronic Venous Insufficiency (CVI). By creating innovative tissue-based solutions, enVVeno Medical aims to enhance the standard of care for patients suffering from debilitating venous conditions. The company is committed to improving patient outcomes while streamlining surgical procedures for healthcare providers. Based in Irvine, California, enVVeno Medical continues to focus on developing technologies that promise to transform the management of venous diseases.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

OnKure Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative cancer therapies. The company specializes in creating less toxic kinase inhibitor drugs and epigenetic therapies, including selective inhibitors of histone deacetylases. Its lead candidate, OKI-179, has demonstrated significant efficacy in preclinical models of hematological and solid tumor cancers, effectively reducing tumor growth both alone and in combination with other targeted therapies. Additionally, OnKure is advancing its HDAC3 selective inhibitor, OKI-422, into preclinical toxicology studies. The company's drug candidates are designed to directly target malignant cells, enhance the effects of small molecule therapies, and optimize the tumor microenvironment for improved checkpoint inhibition, addressing unmet medical needs in cancer treatment.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

InSightec Ltd. specializes in developing and distributing the Exablate platform, which employs MR-guided focused ultrasound technology for non-invasive medical treatments in oncology and gynecology. The company offers solutions such as Exablate Neuro, designed for personalized thalamotomy to address movement disorders and pain without invasive surgery, and a thermal ablation technique for the treatment of uterine fibroids, which alleviates symptoms while minimizing damage to surrounding tissues. Founded in 1999 and headquartered in Tirat Carmel, Israel, InSightec has expanded its presence globally with operations in Europe, Asia, and the Americas. The Exablate system has received various regulatory approvals, including CE marks and FDA approval, and has been recognized with multiple innovation awards for its contributions to healthcare. In addition to its medical devices, InSightec provides clinical training, business support, maintenance, and customer services to healthcare facilities using its technology.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing implanted drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company utilizes a refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of its formulation of the anti-epileptic drug valproic acid, known as CT-010. This innovative approach aims to bypass the blood-brain barrier, enhancing treatment outcomes for patients with chronic neurological conditions. Founded in 2010, Cerebral Therapeutics is dedicated to improving the lives of individuals affected by uncontrolled neurological diseases.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

enVVeno Medical Corp is a medical device company dedicated to advancing the treatment of venous disease through the development of bioprosthetic devices. The company's flagship product, the VenoValve, represents a pioneering surgical implant designed to address severe deep venous Chronic Venous Insufficiency (CVI). By creating innovative tissue-based solutions, enVVeno Medical aims to enhance the standard of care for patients suffering from debilitating venous conditions. The company is committed to improving patient outcomes while streamlining surgical procedures for healthcare providers. Based in Irvine, California, enVVeno Medical continues to focus on developing technologies that promise to transform the management of venous diseases.

Bridge to Life is a U.S.-based company headquartered in Northbrook, Illinois, dedicated to enhancing organ transplantation through the development and licensing of innovative preservation solutions and technologies. As a leading supplier of preservation products worldwide, the company focuses on advancing organ preservation and machine perfusion techniques, which are crucial for the effective storage of intra-abdominal organs. By collaborating closely with surgeons and transplant professionals, Bridge to Life continually explores emerging scientific advancements and preservation technologies to improve the quality of service provided to organ procurement organizations and transplant centers.

Bridge to Life is a U.S.-based company headquartered in Northbrook, Illinois, dedicated to enhancing organ transplantation through the development and licensing of innovative preservation solutions and technologies. As a leading supplier of preservation products worldwide, the company focuses on advancing organ preservation and machine perfusion techniques, which are crucial for the effective storage of intra-abdominal organs. By collaborating closely with surgeons and transplant professionals, Bridge to Life continually explores emerging scientific advancements and preservation technologies to improve the quality of service provided to organ procurement organizations and transplant centers.

Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Juno Diagnostics, Inc. is a health technology company based in San Diego, California, that specializes in cell-free DNA-based prenatal testing. Founded in 2017, the company aims to democratize access to genetic information by developing simple, cost-effective devices for point-of-need genetic testing. Juno's technology allows for noninvasive prenatal tests that enhance sample collection and provide high-quality test results without the challenges associated with traditional testing methods, such as high costs, long lead times, and the need for phlebotomy. In addition to prenatal testing, Juno is also involved in developing genetic testing tools and applications in areas such as epigenetics, inherited diseases, and cancer diagnostics.

OnKure Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative cancer therapies. The company specializes in creating less toxic kinase inhibitor drugs and epigenetic therapies, including selective inhibitors of histone deacetylases. Its lead candidate, OKI-179, has demonstrated significant efficacy in preclinical models of hematological and solid tumor cancers, effectively reducing tumor growth both alone and in combination with other targeted therapies. Additionally, OnKure is advancing its HDAC3 selective inhibitor, OKI-422, into preclinical toxicology studies. The company's drug candidates are designed to directly target malignant cells, enhance the effects of small molecule therapies, and optimize the tumor microenvironment for improved checkpoint inhibition, addressing unmet medical needs in cancer treatment.

MIVI Neuroscience, Inc. is a medical device company based in Eden Prairie, Minnesota, that specializes in developing and commercializing solutions for neurointerventional procedures. Founded in 2013, the company offers a range of innovative products designed to enhance patient outcomes by improving the safety and efficacy of treatments for ischemic stroke. Its product portfolio includes high flow tubing, diagnostic and guide catheters, and aspiration pumps, as well as embolic protection and clot retrieval devices. MIVI Neuroscience aims to reduce complications and procedure times, thereby expanding treatment options for healthcare professionals and their patients.

Earli is a company focused on developing innovative cancer treatment devices that utilize synthetic biomarkers for early cancer detection. The company's approach involves a novel gene therapy technique known as Synthetic Biopsy, which prompts cancer cells to produce synthetic, non-human biomarkers. These biomarkers can be detected through various means, including blood, urine, or breath, allowing for timely tracking and treatment of cancer. By facilitating the early identification of cancer when it is still homogeneous, Earli aims to significantly enhance survival rates. Their technology not only aids in detection but is also applicable for therapeutic interventions, thereby personalizing treatment and improving patient outcomes.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Prometheus Biosciences, established in 1995 and headquartered in San Diego, California, specializes in developing and commercializing innovative pharmaceutical and diagnostic products. The company's portfolio includes tests that enable physicians to provide personalized patient care, such as monitoring drug and anti-drug antibody levels, diagnosing and prognosticating inflammatory bowel disease (IBD), and detecting celiac disease and lactose intolerance. Prometheus also offers therapeutic products like Entocort EC for treating Crohn's disease and has agreements to develop and market other drugs. The company's commitment to innovation positions it as a leader in precision healthcare, particularly in gastroenterology.

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

CereVasc, Inc. is a medical device company dedicated to developing innovative, minimally invasive treatments for neurological diseases. Founded in 2014 and based in Auburndale, Massachusetts, the company focuses on its flagship product, the eShunt System. This system provides an endovascularly deliverable cerebrospinal fluid shunt along with necessary delivery components, designed to eliminate the need for invasive surgical procedures, general anesthesia, and prolonged hospitalization associated with traditional treatments for communicating hydrocephalus. By offering a less invasive option, the eShunt System aims to enhance patient outcomes and reduce the overall costs of surgical interventions for this serious condition.

Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing implanted drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company utilizes a refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of its formulation of the anti-epileptic drug valproic acid, known as CT-010. This innovative approach aims to bypass the blood-brain barrier, enhancing treatment outcomes for patients with chronic neurological conditions. Founded in 2010, Cerebral Therapeutics is dedicated to improving the lives of individuals affected by uncontrolled neurological diseases.

AgaMatrix, Inc. develops and manufactures advanced diabetes management products, including biosensors and blood glucose monitoring systems. The company is known for its WaveSense technology, which personalizes glucose testing to enhance accuracy by mitigating errors from variations in blood samples and environmental conditions. Its product offerings include mobile blood glucose meters, the AgaMatrix Diabetes Manager software for comprehensive diabetes tracking, and Zero-Click, a simplified data management system for diabetes information. AgaMatrix has established strategic partnerships with Biocorp Production, Sanofi, Perrigo, and CVS/pharmacy, facilitating the distribution of its products through retail channels. Incorporated in 2001 and headquartered in Salem, New Hampshire, AgaMatrix holds over 160 patents worldwide, reflecting its commitment to innovation in diabetes care.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

PanTheryx is a U.S.-based medical nutrition company dedicated to the research, development, and commercialization of products aimed at promoting intestinal health. Founded in 2007 and headquartered in Boulder, Colorado, the company focuses on addressing the dietary needs of children suffering from infectious diarrhea while also supporting overall gastrointestinal health. PanTheryx operates a proprietary technology platform that facilitates clinical testing and the development of its products, which are regulated as medical foods, foods for special dietary use, and dietary supplements by the FDA. Additionally, the company targets serious gastrointestinal microbiome-related health conditions, enabling both pharmaceutical and consumer healthcare companies to provide effective anti-diarrheal solutions.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

Medicrea is a specialized spinal implant company committed to delivering innovative technologies for the global healthcare market. With over 18 years of experience, the company offers a comprehensive range of patented products designed to enhance patient outcomes and support healthcare professionals. Medicrea develops personalized analytical services and implant systems aimed at providing long-lasting pain relief for patients undergoing spinal surgery. Its product portfolio includes the UNiD Adaptive Spine Intelligence technology, as well as the PASS Range, Cervical Range, and TH-LUMBAR Range, each tailored to meet specific clinical needs.

Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

AEGEA Medical, Inc. is a medical technology company based in Menlo Park, California, focused on improving women's healthcare through innovative treatment options. The company has developed a water vapor ablation system, known as Mara, which provides a safe and effective method for endometrial ablation to treat heavy menstrual bleeding, or menorrhagia. This FDA-approved technology allows for a straightforward, office-based procedure that typically takes only minutes to perform. AEGEA is dedicated to enhancing patient outcomes and expanding access to effective therapies, while also supporting physicians in delivering these procedures with confidence and ease. Founded in 2008, AEGEA Medical is committed to pioneering advancements in women’s health.

Counsyl is a health technology company specializing in DNA screening for individuals and families. It aims to enhance health outcomes by providing critical genetic information that can influence behaviors, preventative measures, and overall health preparedness. Operating a modern clinical laboratory, Counsyl has screened over 500,000 patients and collaborated with more than 6,000 health professionals. The company employs advanced technology, including custom robotic automation, to efficiently process blood and saliva samples, allowing for precise analysis of DNA. Counsyl's innovative approach has garnered recognition, including the Wall Street Journal's Innovation Award for Medicine and a spot on Scientific American's list of "Top 10 World Changing Ideas." Its Family Prep Screen has enabled many to uncover vital information before starting families, while its services have expanded to include informed pregnancy and cancer screening.

Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Motus GI is a medical technology company that focuses on improving outcomes in endoscopy and enhancing patient experiences in the diagnosis and management of gastrointestinal conditions. Based in Fort Lauderdale, Florida, and with operations in Israel, the company has developed the Pure-Vu System, a medical device designed to assist in the cleaning of poorly prepared colons during colonoscopy procedures. This device aims to facilitate better visualization and improve the overall effectiveness of the colonoscopy, contributing to the early detection and prevention of colorectal cancer and other gastrointestinal diseases. The Pure-Vu System has received clearance from the U.S. Food and Drug Administration and is also CE marked for use in the European Economic Area.

Establishment Labs, founded in 2004, is a medical technology company based in Alajuela, Costa Rica. It specializes in designing, manufacturing, and marketing silicone-filled breast and body shaping implants, primarily under the Motiva Implants brand. The company offers a wide range of breast implants with various surface, shape, size, base, and projection choices. Additionally, Establishment Labs provides Q Inside Safety Technology, a radio frequency identification transponder for implant data access, and Divina 3D imaging technology for surgical planning. Its products are sold through exclusive distributors and direct sales to plastic surgeons, hospitals, and clinics in over 80 countries worldwide. The company's manufacturing facilities adhere to strict FDA and ISO standards.

VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative cellular immunotherapies for the treatment of hematological cancers and solid tumors. The company is advancing its product candidates, including BPX-601, an autologous GoCAR-T therapy aimed at solid tumors expressing prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy targeting solid tumors that express human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control of immune system components to enhance therapeutic efficacy. The company collaborates with various institutions, including Adaptimmune Therapeutics and Baylor College of Medicine, to further its research and development efforts. Founded in 2004, Bellicum Pharmaceuticals continues to make strides in cancer treatment through its novel immunotherapeutic approaches.

Virobay Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on developing and commercializing novel therapies for various medical conditions, including neuropathic pain, autoimmune diseases, liver fibrosis, cancer, and Alzheimer's disease. The company's pipeline includes VBY-129, a cathepsin S inhibitor aimed at treating neuropathic pain and Crohn's disease, and VBY-376, an orally-administered cathepsin B inhibitor for liver fibrosis associated with nonalcoholic steatohepatitis. Additionally, VBY-825 is designed to inhibit multiple cathepsins to mitigate autoimmune attacks on bile ducts and reverse fibrosis. Virobay has also licensed VBY-891 to LEO Pharma A/S for specific dermatological uses, such as psoriasis. Founded in 2006, Virobay is dedicated to addressing significant unmet medical needs through its cysteine cathepsin platform, which focuses on developing safer and more effective treatments by regulating essential cellular processes.